What Increases Your Risk of Fatty Liver?

Separate a contributing factor from a diagnosis

Fatty liver or hepatic steatosis is fat accumulation in the liver that may have metabolic, alcohol-related, medicine-related, or other causes. Fatty liver often causes no early symptoms. MASLD is a newer term when metabolic criteria are met; a scan alone cannot establish steatohepatitis or fibrosis stage. This article focuses on risk factors.

Fatty liver is often silent. MASLD terminology applies when metabolic criteria are met; fibrosis risk requires evaluation. Start with “Cardiometabolic risks”: Diabetes, blood pressure, lipids, and other metabolic factors may contribute to MASLD when diagnostic criteria are met. Read the fatty liver overview for the broader context.

Then consider “Medicines and other causes” and “Risk isn't a diagnosis” separately. Review metabolic risk, alcohol, medicines, viral hepatitis risk, liver tests, and fibrosis scoring with elastography when appropriate. The fatty liver diagnosis describes a relevant next step.

For this discussion of risk factors, “Cardiometabolic risks” is a starting clue. Fatty liver often causes no early symptoms. MASLD is a newer term when metabolic criteria are met; a scan alone cannot establish steatohepatitis or fibrosis stage. The AASLD - New MASLD nomenclature informs the clinical distinction; it cannot determine an individual's diagnosis from a symptom count.

An additional source, NIDDK - NAFLD diagnosis, informs evaluation and management. In this article, “Medicines and other causes” deserves review: Some drugs and medical conditions may cause steatosis, so a metabolic label should follow an appropriate review.

Bring original reports and a dated history for “Risk isn't a diagnosis.” Review metabolic risk, alcohol, medicines, viral hepatitis risk, liver tests, and fibrosis scoring with elastography when appropriate. If a test is negative, ask what it excluded and which plausible explanation remains.

First identify exactly what happened: Diabetes, blood pressure, lipids, and other metabolic factors may contribute to MASLD when diagnostic criteria are met. Note onset, frequency, severity, associated symptoms, and relevant medicines or procedures.

Next decide which finding would change care. Some drugs and medical conditions may cause steatosis, so a metabolic label should follow an appropriate review. Review metabolic risk, alcohol, medicines, viral hepatitis risk, liver tests, and fibrosis scoring with elastography when appropriate.

Finally agree on follow-up and escalation. No single factor or count proves steatohepatitis, and imaging alone cannot determine the cause of fat. Promptly assess jaundice or new swelling; vomiting blood, black stool, or confusion needs emergency care.

The same label can lead to different actions because location, severity, and confirmed cause differ. For “Medicines and other causes,” treat the established cause, address cardiometabolic health with an individualized plan, and follow fibrosis risk rather than symptoms alone.

For “Cardiometabolic risks,” treat the established cause, address cardiometabolic health with an individualized plan, and follow fibrosis risk rather than symptoms alone. Choose a symptom, finding, or treatment response that can be checked at a named follow-up date.

Keep the original result for “Medicines and other causes,” record what has changed since it was obtained, and confirm who receives pending tests.

Comfort alone may be an incomplete endpoint. If “Risk isn't a diagnosis” persists or new findings appear, return to the diagnostic question and revise the plan.

Promptly assess jaundice or new swelling; vomiting blood, black stool, or confusion needs emergency care.

While considering risk factors for fatty liver or hepatic steatosis, emergency symptoms should not wait for a portal reply or a routine office visit. State the onset, severity, medicines, and any recent imaging or procedure result.

• New jaundice or abdominal swelling
• Unexpected liver test changes or advanced fibrosis risk
• Vomiting blood, black stool, or confusion

• Record when “cardiometabolic risks” began and what accompanied it.
• Ask what result distinguishes “medicines and other causes” from another possible explanation.
• Agree on the treatment goal and who will review the next result.
• Reassess the plan if “risk isn't a diagnosis” persists.
• Use the urgent thresholds for fatty liver or hepatic steatosis when symptoms change.